<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05126810</url>
  </required_header>
  <id_info>
    <org_study_id>2021-0151</org_study_id>
    <secondary_id>NCI-2021-10716</secondary_id>
    <secondary_id>2021-0151</secondary_id>
    <nct_id>NCT05126810</nct_id>
  </id_info>
  <brief_title>Willingness to Participate in a Trial Comparing Standard Genetic Counseling Versus Personalized Genetic Counseling</brief_title>
  <official_title>Evaluate Willingness to Participate in a Trial Comparing Standard Genetic Counseling Versus Personalized Genetic Counseling Based on LFSPRO-ShinyApp Data</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <brief_summary>
    <textblock>
      This study evaluates patients willingness to participate in a trial comparing standard&#xD;
      genetic counseling versus personalized genetic counseling. Collecting information from&#xD;
      patients may help researchers learn why patients may or may not take part in the future study&#xD;
      that compares standard genetic counseling to personalized genetic counseling.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To evaluate patients' willingness to participate in a future randomized trial comparing&#xD;
      standard genetic counseling versus personalized genetic counseling based on Li-Fraumeni&#xD;
      syndrome patient reported outcome (LFSPRO) ShinyApp data.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients complete a questionnaire over 15-20 minutes. Patients positive for a TP53 mutation&#xD;
      complete an additional questionnaire over 15-20 minutes within 1 month after test results.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2022</start_date>
  <completion_date type="Anticipated">August 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patient willingness to participate in a future randomized trial comparing standard genetic counseling versus personalized genetic counseling based on LFSPRO ShinyApp data</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Li-Fraumeni Syndrome</condition>
  <arm_group>
    <arm_group_label>Observational (questionnaire)</arm_group_label>
    <description>Patients complete a questionnaire over 15-20 minutes. Patients positive for a TP53 mutation complete an additional questionnaire over 15-20 minutes within 1 month after test results.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Complete questionnaire</description>
    <arm_group_label>Observational (questionnaire)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Receive receiving genetic counseling specifically for TP53 genetic testing&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals age 15 or older OR parent/guardian of a patient younger than 15 years (if&#xD;
             age 15-17, the patient will provide assent and parent/guardian will provide consent)&#xD;
&#xD;
          -  English fluency&#xD;
&#xD;
          -  Receive genetic counseling specifically for TP53 genetic testing and who consent to&#xD;
             undergo TP53 genetic testing OR individuals whose genetic testing indicates a TP53&#xD;
             germline mutation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals who are non-English speaking&#xD;
&#xD;
          -  Individuals having low suspicion for a TP53 germline mutation during pretest&#xD;
             counseling and test negative for a TP53 mutation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Banu Arun</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Banu Arun</last_name>
    <phone>713-792-2360</phone>
    <email>barun@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Banu Arun</last_name>
      <phone>713-792-2360</phone>
      <email>barun@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Banu Arun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>M.D. Anderson Cancer Center</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 25, 2021</study_first_submitted>
  <study_first_submitted_qc>November 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Li-Fraumeni Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

